Thought Leader Insight & Analysis Report - Rheumatology Q3 2011

Medpredict, October 2011, Pages: 149

Rheumatology Thought Leader Panel #33 is a thought exercise conducted with eight North American (n=5) and European (n=3) rheumatologists in September 2011. Medpredict cover a broad range of rheumatologic conditions, with each Panelist having specific areas of specialization: rheumatoid arthritis, psoriatic arthritis, lupus, osteoporosis, gout, osteoarthritis. In this report Medpredict share each Panelist’s “Fantasy Formulary”, and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned. The purpose of this exercise was to identify their “must have” branded and generic drugs for their real-world practice in the year 2016.

EXECUTIVE SUMMARY

Introduction

Methods

Results
- Table 1*: 2011 Composite Scores by Drug Class
- Table 2: 2011 Composite Scores for all Drugs Mentioned
- Table 3: Top Ten Drugs (2009)
- Table 4: European Panelist Responses 2011
- Table 5: European Panelist Responses 2009
- Table 6: North American Panel Responses 2011
- Table 7: North American Panel Responses 2009

Discussion - Preferred Classes
- JAK
- B-cell
- Lupus
- IL6
- IL17

PANEL FAVORITES

JAK
- tofacitinib (Pfizer)
- INCB-28050 (Incyte / Lilly)
- VX-509 (Vertex)

B-Cell
- Benlysta (belimumab; GSK / HGS)
- epratuzumab (UCB)
- atacicept (Merck-Serono / ZymoGenetics)
- blisibimod (AMG-623; Anthera)
- Arzerra (ofatumumab; GlaxoSmithKline / Genmab)
- PCI-32765 (Pharmacyclics)
- tabalumab LY2127399 (Lilly)

IL6
- Actemra/RoActemra (tocilizumab; Chugai / Roche)
- ALD-518/ BMS-945429 (BMS / Alder)
- sirukumab (Johnson & Johnson)
- olokizumab/CDP-6038 (UCB)
- Other IL-6 (sarilumab/Sanofi-Aventis / Regeneron)

IL17
- IL17 (AIN-457/secukinumab/Novartis; ixekizumab / Lilly, AMG-827/Amgen)

Syk
- fostamatinib (AstraZeneca / Rigel)

Antiresorptive / RANKL
- odanacatib (Merck)
- Prolia; denosumab (Amgen)

TNF
- Biosimilar TNF
- TNF-K-003 TNF-alpha kinoid vaccination (Neovacs)

CTLA4
- Orencia (abatacept; BMS)

URAT1
- lesinurad (RDEA-594; Ardea)

Xanthine Oxidase

Bone Anabolic
- AMG-785 (Amgen / UCB)
- 38A BMP-7 (Stryker)

IFNa
- Rontalizumab (Genentech)
- sifalimumab (MEDI-545; Medimmune)

IL1
- Arcalyst; rilonacept (Regeneron)
- Ilaris; canakinumab (Novartis)

IL23
- Stelara (ustekinumab; Centocor)

Steroid
- Lodotra (modified-release prednisone; Nitec)

C5A
- MP-435 (Mitsubishi Tanabe)

Proteasome Inhibition
- bortezomib(Millennium), carfilzomib (Onyx)

GM-CSF
- Regulatory T-Cell
- BT-061 (Abbott / Biotest)

THOUGHT LEADER INTERVIEWS
- Interview BJE02594
- Interview BJE02595
- Interview BJE02596
- Interview BJE02597
- Interview BJE02598
- Interview BJE02599
- Interview BJE02601

Customers who bought this item also bought

• Medical Nutrition - A Global Market Overview
• Diabetes Diagnostics - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Gene Amplification Technologies - Global Strategic Business Report
• Proteomics - Global Strategic Business Report
• Thought Leader Insight & Analysis Report - Diabetes/Obesity Q4 2010
• Global Biopharmaceutical Market Report & Forecast (2012-2017)
• Syringes (Disposable and Reusable) - Global Strategic Business Report
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast